A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer
Oncologists reported strong agreement with established guidelines for the use of OFS in the treatment of early-stage hormone receptor-positive breast cancer. However, our findings indicate a need for guidance regarding the determination of menopausal status in the setting of amenorrhea and monitoring of ovarian function.
Authors
- Dinorah Martinez Tyson (ORCID: https://orcid.org/0000-0002-9390-5364)
- Bo Hu (ORCID: https://orcid.org/0000-0002-5256-505X)
- Clement K. Gwede (ORCID: https://orcid.org/0000-0003-1630-7333)
- Kimberley Lee (ORCID: https://orcid.org/0000-0002-3346-0885)
- Susan T. Vadaparampil (ORCID: https://orcid.org/0000-0002-1052-6917)
- Heather S.L. Jim (ORCID: https://orcid.org/0000-0001-7353-3711)
- N. Lynn Henry
- Carley Geiss (ORCID: https://orcid.org/0000-0003-3800-1132)
- Hatem Soliman (ORCID: https://orcid.org/0000-0001-6644-2264)
- Dawn L. Hershman (ORCID: https://orcid.org/0000-0001-8807-153X)
Institutions
- Breast Cancer Research Foundation (US)
- University of South Florida (US)
- University of Michigan (US)
- Moffitt Cancer Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1007/s10549-025-07734-2
- Citations
- 1
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- National Comprehensive Cancer Network